Tecentriq could be more than an also-ran in SCLC, says GlobalData

13 July 2018

Roche’s (ROG: SIX) immuno-oncology drug Tecentriq (atezolizumab) has largely been an outsider to the leaders in the first wave of I-O treatments, Bristol-Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab) and Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab).

But according to new analysis from the data and analytics company GlobalData, the planned submission of Tecentriq for prospective marketing approval in the USA and Europe by Roche could put the Swiss pharma giant in a very strong position within the small cell lung cancer (SCLC) treatment space.

This follows the news that Roche’s Phase III IMpower133 study evaluating Tecentriq with carboplatin and etoposide, the standard-of-care chemotherapy regimen in treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), met its co-primary endpoints of overall survival and progression-free survival at the first interim analysis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK